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Abstract
Angiogenesis is involved in the pathogenesis of inflammatory
arthritis, but little is known about the role of lymphangiogenesis
in this setting. Here, we examined whether tumor necrosis factor
(TNF) stimulates osteoclast precursors (OCPs) to produce the
lymphatic growth factor, vascular endothelial growth factor-C
(VEGF-C), and induce lymphangiogenesis. We used TNF-
transgenic (Tg) mice and mice with serum-induced arthritis.
OCPs were purified by fluorescence-activated cell sorting of
CD11b+/Gr-1-/lo blood or bone marrow cells and subjected to
microarray analysis or were generated from spleen or joint cells
and treated with TNF. Expression of VEGFs was analyzed and
examined by real-time reverse transcription-polymerase chain
reaction and Western blotting. Immunostaining and magnetic
resonance imaging were used to quantify lymphatic vessels and
volumes of synovium and draining lymph nodes. TNF stimulated
VEGF-C expression by OCPs and increased nuclear factor-
kappa B (NF-κB) binding to an NF-κB sequence in the VEGF-C
promoter. OCPs from joints of TNF-Tg mice express high levels
of VEGF-C. Lymphatic vessel numbers and size were markedly
increased in joint sections of TNF-Tg mice and mice with serum-
induced arthritis. The severity of synovitis correlated with
draining lymph node size. In summary, TNF induces OCPs to
produce VEGF-C through NF-κB, leading to significantly
increased lymphangiogenesis in joints of arthritic mice. The
lymphatic system may play an important role in the pathogenesis
of inflammatory arthritis.
Introduction
Joint disease in rheumatoid arthritis (RA) is characterized by
inflamed hyperplastic synovial tissue or 'pannus' formation [1].
Pannus is composed of various cell types that produce a vast
array of inflammatory mediators, including cytokines and
chemokines that destroy the extracellular matrix in the joint by
direct and indirect mechanisms. Pannus is extremely vascular,
providing portals of entry for effector cells to enter the joint
from the circulation and mediate joint destruction via autocrine
and paracrine mechanisms. As a result of neovascularization,
inflammatory cell infiltration, and concomitant synovial cell
hyperplasia, the volumes of the synovium and synovial fluid
increase, resulting in joint swelling and pain [2]. Thus, inhibi-
tion of new blood vessel formation has been proposed as an
important therapeutic approach for patients with inflammatory-
erosive arthritis [3].
The lymphatic circulation has been known for many years to be
an important secondary vascular system to remove fluid, mac-
romolecules, and cells from the interstitial spaces, and it func-
tions as a 'compensatory' system for blood circulation.
However, studies of the lymphatic system have been ham-
pered until recently by the lack of markers that definitively dis-
tinguish blood from lymphatic vessels and a paucity of
knowledge about growth factors specific to lymphatic
endothelial cells. Gene array analysis comparing lymphatic
endothelial cells and blood vascular endothelial cells has
recently identified numerous previously unknown lineage-spe-
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cific markers for blood and lymphatic vascular endothelium.
Newly identified lymphatic endothelium-specific markers
include [4] lymphatic endothelial hyaluronan receptor 1
(LYVE-1), prospero-related homeobox 1, vascular endothelial
growth factor receptor 3 (VEGFR-3), and the mucin-type
transmembrane glycoprotein, podoplanin [5-8].
In studies using these lymphatic markers, several factors, such
as VEGF-A, platelet-derived growth factor (PDGF)-BB, and
fibroblast growth factor, have been shown to affect lymphang-
iogenesis [9]. However, the most specific and potent lym-
phatic growth factors reported to date are VEGF-C and
VEGF-D [10,11], members of the VEGF family. These differ
from VEGF-A (also named VEGF) in that they promote prolif-
eration, migration, and survival of lymphatic vascular endothe-
lial cells through the VEGFR-3 signaling pathway [12]. This
appears to be a non-redundant function because VEGF-C-/-
mice are embryonic lethal due to the lack of lymphatic vessels
[12]. Under physiologic conditions, VEGF-C is expressed
most prominently in the heart, lymph nodes, placenta, and gut
[13] but is also expressed by many cancer cells, which can
induce lymphatics in metastases. Recent studies reported that
VEGF-C is also expressed by CD11b+ myeloid cells that have
migrated to inflammatory sites in several animal models of
inflammation [14-17], such as corneal transplantation and
bacterial lung infection. It was speculated that inflammatory
cytokines, such as tumor necrosis factor (TNF) or interleukin 1
(IL-1), stimulate these CD11b+  cells to produce VEGF-C
because TNF and IL-1 increase VEGF-C expression in human
lung fibroblasts and human umbilical vein endothelial cells in
vitro [18,19]. However, it has not been formally proven that
these cytokines promote VEGF-C expression by CD11b+
cells, and the mechanisms involved are not known.
CD11b antigen is a pan marker for myeloid lineage cells,
which also give rise to osteoclasts. We used a combination of
fluorescence-activated cell sorting (FACS) and osteoclas-
togenesis and colony-forming assays to demonstrate that, in
peripheral tissues, only CD11b+/Gr-1-/lo cells have osteoclas-
togenic potential [20]. Thus, we termed CD11b+/Gr-1-/lo cells
osteoclast precursors (OCPs), although this population in
bone marrow and spleen also contains macrophage and den-
dritic cell precursors. Over the last 2 to 3 years, immune cells
and molecules that primarily function in immune responses
have been demonstrated to affect the functions of cells
involved in bone remodeling, particularly osteoclasts [21],
which has led to development of the new field of osteoimmu-
nology. We have pursued this line of investigation with OCPs
because they belong to a subset of macrophages that can be
activated to produce autocrine and paracrine factors that con-
tribute to inflammation and autoimmunity [22]. In our micro-
array analysis of RNA from OCPs from TNF-transgenic (Tg)
and wild-type (WT) mice, we found that VEGF-C expression is
significantly increased in cells from TNF-Tg mice, suggesting
that VEGF-C-mediated biologic events (for example, lym-
phangiogenesis) may be involved in the pathogenesis of arthri-
tis. In this study, we used recently developed anti-lymphatic
marker antibodies and contrast-enhanced magnetic reso-
nance imaging (MRI) to demonstrate that TNF-Tg mice have a
significant increase in the number and size of synovial lym-
phatic vessels compared with their WT littermates. Further-
more, the severity of erosive synovitis correlates with the
lymphatic drainage capacity to local lymph nodes. Together,
these findings demonstrate significant changes in lymphatic
architecture and draining potential around inflamed joints of
arthritic mice and suggest the possible involvement of the lym-




TNF-Tg mice (Tg 3647 line) in a CBA × C57BL/6 background
were originally obtained from George Kollias (The Biomedical
Sciences Research Center, Greece). We backcrossed them
with C57BL6 mice for seven generations [20]. All TNF-Tg
mice used in this study were 4 to 8 months old with severe
joint synovitis and bone and cartilage destruction. WT litterma-
tes were used as controls. TNF-Tg mice were identified by tail
polymerase chain reaction (PCR) genotyping and paw defor-
mation. KRN-TCR-Tg mice were obtained from Drs. Diane
Mathis and Christophe Benoist (Harvard University, Cam-
bridge, MA, USA) [23]. K/B × N mice were generated by
breeding male KRN-TCR-Tg mice with female non-obese dia-
betic mice (The Jackson Laboratory, Bar Harbor, ME, USA).
Serum was collected from 6- to 12-week-old K/B × N arthritic
mice, pooled, and stored at -80°C. To generate mice with
serum-induced arthritis (SIA), 4- to 5-week-old BALB/c mice
were injected with K/B × N serum intraperitoneally (10 μL/
gram body weight) on day 1 and day 3. Paw swelling and red-
ness usually occurred the day after the first injection, peaked
at 7 to 14 days, and declined thereafter. The Institutional Ani-
mal Care and Use Committee of the University of Rochester
(Rochester, NY, USA) approved all studies.
Reagents
Recombinant murine TNF-α was purchased from R&D Sys-
tems, Inc. (Minneapolis, MN, USA). Allophycocyanin-, fluores-
cein isothiocyanate (FITC)-, and phycoerythrin-anti-mouse
CD11b (M1/70) were purchased from eBiosciences (San
Diego, CA, USA); FITC-anti-mouse Gr-1 (RB6-8C5) from BD
Pharmingen (San Diego, CA, USA); rabbit polyclonal antibody
to VEGF-C (H-190) from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA); rabbit polyclonal antibody to LYVE-1
from Abcam (Cambridge, MA, USA); mouse monoclonal anti-
body to CD31 (Mec13.3) from Biocare Medical LLC (Con-
cord, CA, USA); Alexa Fluor 488 goat anti-hamster
immunoglobulin G (IgG) from Molecular Probes Inc. (now part
of Invitrogen Corporation, Carlsbad, CA, USA); and Alexa
Fluor 546 F(ab')2 fragment of goat anti-rabbit IgG (H+L) andAvailable online http://arthritis-research.com/content/9/6/R118
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To-Pro-3 iodid (642/661) were purchased from Invitrogen
Corporation.
Generation of osteoclast precursors
OCPs were generated from two sources:
(a) Spleen. Splenocytes were extracted from spleens of 8- to
12-week-old C57/B6 WT mice through a fine wire mesh, and
red blood cells were lyzed with NH4Cl (StemCell Technolo-
gies, Vancouver, BC, Canada) on ice for 10 minutes. The cells
were then washed twice with medium and cultured with con-
ditioned medium from a macrophage colony-stimulating factor
(M-CSF)-producing cell line [24] (1:20 dilution) for 3 days to
enrich for OCPs, as we described previously [25].
(b) Joints. Ankle and wrist joints were isolated from TNF-Tg
mice and WT littermates according to published protocols
[26,27] with minor modifications. In brief, mice were sacrificed
and skin and muscle were removed from their limbs. Long
bones together with a front or rear paw were cut from the
limbs. Forceps were used to loosen the joints. The joints were
then cut open and digested with 1 mg/mL of collagenase
(Sigma-Aldrich, St. Louis, MO, USA) at 37°C for 3 hours with
rotation. Cells were then filtered and used for cultures or
FACS analysis.
Affymetrix gene chip analysis
CD11b+/Gr-1-/lo OCPs were purified by flow sorting from
peripheral blood and bone marrow of TNF-Tg mice and age-
matched WT mice by a FACSVantage SE Turbo sorter (Bec-
ton, Dickinson and Company, Franklin Lakes, NJ, USA), as we
described previously [20,28]. To obtain enough RNA from
samples, bone marrow OCPs were pooled from 7 TNF-Tg
mice or 11 WT mice and peripheral blood OCPs were from
pooled from 7 TNF-Tg mice or 23 WT mice. Two completely
independent experiments were performed. Total RNA was
prepared using TRIzol (Invitrogen Corporation), processed,
and hybridized to MG-U74Av2 gene chips according to
Affymetrix protocols (Affymetrix, Santa Clara, CA, USA). Chips
were scanned and analyzed using the GeneTraffic (version
3.2) microarray data analysis software (Lobion Informatics, La
Jolla, CA, USA). In each group, WT samples were set as the
baseline. Data were presented as the fold increase of samples
from TNF-Tg mice over WT samples (baseline sample).
Real-time quantitative reverse transcription-polymerase 
chain reaction
Total RNA was extracted using TRIzol reagent, and cDNA was
synthesized by an RNA PCR Core Kit (Applied Biosystems,
Foster City, CA, USA). Quantitative PCR amplification was
performed with gene-specific primers using an iCycler iQ Mul-
tiple-Color Real-Time PCR Detection System (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA), as we described previously
[25,28]. The primer sequences are listed in Table 1. Expres-
sion levels were normalized relative to β-actin in the same sam-
ple. For each sample, we first obtained the ΔCT (difference in
threshold cycle values), which is equal to CT (target gene) – CT
(β-actin). We then used control (for example, phosphate-buff-
ered saline [PBS]-treated) values as baseline to obtain the
ΔΔCT, which is equal to the ΔCT of the sample minus the ΔCT
of the baseline. Finally, we set the baseline as '1', and thus the
fold change of each sample is equal to 2-ΔΔCT.
Table 1
Sequences of primers used in the real-time reverse transcription-polymerase chain reaction
Genes Sequences of primers Accession number Target sites Size (base pairs)
VEGF-A F: 5'-TTTACTGCTGTACCTCCACCA-3' M95200 125–423 298
R: 5'-ATCTCTCCTATGTGCTGGCTTT-3'
VEGF-B F: 5'-CCTGGAAGAACACAGCCAAT-3' NM_011697 537–701 165
R: 5'-GGAGTGGGATGGATGATGTC-3'
VEGF-C F: 5'-GGGAAGAAGTTCCACCATCA-3' NM_009506 1258–1392 135
R: 5'-ATGTGGCCTTTTCCAATACG-3'
VEGF-D F: 5'-GCTGTCACTGTTGCCCACTA-3' NM_010216 1423–1611 207
R: 5'-CCCTTCCTTTCTGAGTGCTG-3'
PLGF F: 5'-GGGAAGAAGCAAGACATGGA-3' NM_008827 1055–1261 189
R: 5'-ATGTCCTGTCCCATCTCCAG-3'
β-actin F: 5'-ACCCAGATCATGTTTGAGAC-3' X03765 280–503 224
R: 5'-GTCAGGATCTTCATGAGGTAGT-3'
F, forward primer; PLGF, placental growth factor; R, reverse primer; VEGF, vascular endothelial growth factor.Arthritis Research & Therapy    Vol 9 No 6    Zhang et al.
Page 4 of 14
(page number not for citation purposes)
Immunofluorescence staining and imaging cytometry
Cells were cytospun on glass slides and fixed by cold metha-
nol at -20°C for 10 minutes. After washing with PBS, cells
were incubated in 0.1% Triton and blocked with 1% bovine
serum albumin/PBS for 30 minutes at room temperature. The
fixed cells were stained with a mixture of FITC-anti-CD11b and
anti-VEGF-C antibody followed by Alexa Fluor 546 F(ab')2
fragment of goat anti-rabbit IgG (H+L) and by To-Pro-3 iodid.
Immunohistomorphometry of lymphatic vessels
Joint sections from TNF-Tg and WT mice were fixed in 4.5%
phosphate-buffered formalin, decalcified in 14% ethylenedi-
aminetetraacetic acid, and embedded in paraffin wax. Depar-
affinized sections were quenched with 3% hydrogen peroxide
and treated for antigen retrieval for 30 minutes. Adjacent serial
sections were then stained with anti-LYVE-1 or anti-CD31
antibodies. Lymphatic vessels were quantified by a point-
counting method, as we described previously [29]. For each
mouse, two sections were cut at 250 μm apart and the area
and size of LYVE-1+ lymphatic vessels were measured within
the synovial tissue. The size and area of lymphatic vessels
were expressed per square millimeter of synovium.
Electrophoretic mobility shift assay
Raw 264.7 osteoclast/macrophage precursor cells were
serum-starved overnight and then treated with 10 ng/mL of
TNF for 30 and 60 minutes. Nuclear extract preparation and
electrophoretic mobility shift assay (EMSA) were performed
as described previously [30]. The following double-stranded
oligonucleotides were used in this study according to the pub-
lished mouse VEGF-C promoter sequence [18] (only the top
strands are shown): VEGF-C nuclear factor-kappa B (NF-κB)-
like sequence (WT), 5'-GCCCAGGGGGGTCCCCG-
GGAGG-3'; mutated VEGF-C NF-κB-like sequence (mutation
underlined), 5'-GCCCAGGGGATTCTCCGGGAGG-3'; and
SP-1-binding sequence (control; Invitrogen Corporation), 5'-
CGAGCCGGCCCCGCCCATC-3'. For competition assays,
binding reactions were pre-incubated with unlabeled oligonu-
cleotides for 15 minutes at room temperature.
In vivo contrast-enhanced magnetic resonance imaging
A detailed methodology of this new technique in mice will be
published in a separate manuscript [31]. Briefly, mice were
positioned with the right leg in a custom-designed murine knee
coil and scanned in a Siemens 3 Tesla clinical magnet (Sie-
mens AG, Munich, Germany). A high-resolution fat-sup-
pressed T1-weighted sequence (Sagittal T1-weighted FLASH
[fast low-angle shot], repetition time = 45 ms, echo time =
9.03 ms, 192 × 192 pixels, 20 mm × 20 mm field of view, 32
slices of 0.16-mm slice thickness, flip angle = 25°, 1 signal
average, time: 8:28) was then initiated. An intravenous injec-
tion of Gd-DTPA contrast agent (Omniscan; Amersham
Health, now part of GE Healthcare, Little Chalfont, Bucking-
hamshire, UK) was given, and a post-contrast high-resolution
scan (same parameters) was collected. Analysis was per-
formed with Amira 3.1 (TGS; Mercury Computer Systems,
Inc., Chelmsford, MA, USA). An image registration and sub-
traction algorithm on the pre- and post-contrast images in
Amira generated an image of the voxels of contrast enhance-
ment. From this image, a three-dimensional (3D) region of
interest of muscle tissue was used as a measure of delivered
contrast agent, and a threshold of enhancing synovial tissue
was generated from this value. Lymph nodes were traced man-
ually and thresholded to define the margin between the node
and surrounding fat. Tissue volumes (3D) were reconstructed
using a surface generation module in Amira.
Statistics
Data are presented as mean ± standard deviation of three cul-
ture dishes, and all experiments were performed at least twice.
Statistical analyses were performed with Statview statistical
software (SAS Institute Inc., Cary, NC, USA). Differences
among more than two groups were compared using one-way
analysis of variance followed by the Mann-Whitney U test. P
values of less than 0.05 were considered statistically signifi-
cant. Each experiment was repeated at least twice with similar
results.
Results
VEGF-C expression is upregulated in CD11b+/Gr-1-/lo 
osteoclast precursors from tumor necrosis factor-
transgenic mice
Previous studies demonstrated an increase in circulating
OCPs in patients [32] and animals [20] with arthritis and that
OCP frequency is reduced in response to anti-TNF therapy,
suggesting that OCPs may play important roles in the patho-
genesis of arthritis [33]. To screen for novel genes that are dif-
ferentially expressed by OCPs between arthritic and normal
mice, we performed microarrays on RNA isolated from
CD11b+/Gr-1-/lo OCPs from peripheral blood mononuclear
cells and bone marrow pooled from TNF-Tg and WT mice. The
purity of CD11b+/Gr-1-/lo cells was confirmed by FACS. In our
initial bioinformatic screen, we focused on genes encoding
angiogenic factors because they are critical for development
of inflammation and bone erosion in arthritic joints. Among
more than 50 known angiogenic factors (including matrix met-
alloproteinases, adhesion molecules, enzymes, and growth
factors), we found that expression levels of PDGF-B, PDGF
receptor β, and VEGF-C were significantly increased in circu-
lating OCPs of TNF-Tg mice (approximately six-fold in TNF-Tg
over WT OCPs) (Figure 1). Expression levels of these genes
were also increased in bone marrow OCPs but to a lesser
extent. Since TNF is known to induce PDGF signaling [34], we
decided to explore the possibility that VEGF-C has a novel role
in inflammatory arthritis similar to its role in metastatic cancer
[35,36].Available online http://arthritis-research.com/content/9/6/R118
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Tumor necrosis factor stimulates osteoclast precursors 
to produce VEGF-C
To determine whether TNF directly upregulates expression of
VEGF-C by OCPs, we cultured WT spleen cells with M-CSF
for 3 days to generate OCPs, as we described previously [25].
The rationale for using spleen cells rather than bone marrow
cells is that spleen-derived OCPs are closer to circulating
OCPs than bone marrow OCPs in terms of their osteoclast-
forming potency [37] and the increased VEGF-C expression
level in circulating OCPs is more than three times higher than
in bone marrow OCPs (Figure 1). TNF treatment increased
VEGF-C mRNA levels by three- to four-fold in a time- and
dose-dependent manner, beginning at between 4 and 8 hours,
suggesting transcriptional regulation (left panel in Figure 2a).
It also increased VEGF-C protein expression at 24 hours (right
panels in Figure 2a). TNF did not significantly affect expression
of other VEGF members (Figure 2b). Dose-response experi-
ments demonstrated that a low dose of TNF (0.5 ng/mL) is suf-
ficient to stimulate VEGF-C protein expression, supporting an
in vivo role for TNF to induce VEGF-C expression (Figure 2c).
We also examined whether IL-1, another cytokine whose lev-
els are increased significantly in joints of TNF-Tg mice, affects
VEGF-C levels in OCPs. Similar to TNF, IL-1 treatment (by 24
hours) also increased VEGF-C mRNA by two- to three-fold,
but IL-1 + TNF did not have an additive effect (Figure 2d). This
suggests that TNF and IL-1 may use a similar signaling path-
way to regulate VEGF-C expression.
Figure 1
Differential expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) family genes in CD11b+/Gr-1-/lo oste- oclast precursors (OCPs) from tumor necrosis factor-transgenic (TNF-Tg) and wild-type (WT) mice Differential expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) family genes in CD11b+/Gr-1-/lo oste-
oclast precursors (OCPs) from tumor necrosis factor-transgenic (TNF-Tg) and wild-type (WT) mice. CD11b+/Gr-1-/lo cells from peripheral blood and 
bone marrow from TNF-Tg (7 mice per array) and WT (23 mice per array) mice were pooled and purified by flow sorting. The RNA samples were 
subjected to microarray analysis using the GeneChip mouse genome 430A 2.0 array from Affymetrix. The array data on angiogenic gene expression 
were analyzed using GeneTraffic software. The expression ratio was calculated by dividing the mean value of the intensity of RNA signals from two 
separate arrays of TNF-Tg OCPs by that from WT cells.Arthritis Research & Therapy    Vol 9 No 6    Zhang et al.
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Nuclear factor-kappa B mediates tumor necrosis factor-
induced VEGF-C expression
NF-κB is a transcription factor that mediates induction of
genes by TNF in many cell types, including OCPs [38]. NF-κB
also mediates heregulin-beta-1-induced VEGF-C expression
in human breast cancer cells [39]. We found that there is a
putative NF-κB-binding element, GGGGTCCC, at the -108/-
99 region of the mouse VEGF-C promoter, which is at a loca-
tion similar to that in the human promoter [18]. Thus, to deter-
mine whether TNF stimulates binding of NF-κB proteins to this
element in OCPs, we treated Raw 264.7 cells with TNF for 30
and 60 minutes and performed Western blot analysis and
EMSA on nuclear extracts from the cells. TNF treatment for 30
minutes increased nuclear translocation of NF-κB p65 and
p50 proteins (Figure 3a) and specific binding of NF-κB to the
VEGF-C DNA probe (Figure 3b). To further confirm the
involvement of NF-κB in TNF-induced VEGF-C expression, we
treated WT OCPs with an NF-κB inhibitor (Calbiochem, now
Figure 2
Tumor necrosis factor (TNF) increases expression of vascular endothelial growth factor-C (VEGF-C) by osteoclast precursors (OCPs) Tumor necrosis factor (TNF) increases expression of vascular endothelial growth factor-C (VEGF-C) by osteoclast precursors (OCPs). Wild-type 
(WT) spleen cells were cultured with macrophage colony-stimulating factor (M-CSF) for 3 days to enrich for OCPs. OCPs were cultured in 10% 
serum with M-CSF and treated with phosphate-buffered saline (PBS) or TNF (10 ng/mL). (a) Expression of VEGF-C and β-actin mRNA was meas-
ured by real-time reverse transcription-polymerase chain reaction (RT-PCR) at various times (left panel), and protein levels were measured by West-
ern blot analysis (right panels). (b) Expression of VEGF-A, -B, -C, -D, and placental growth factor (PLGF) mRNA was examined in samples treated 
for 24 hours. The fold increases in TNF-treated over PBS-treated cells at a given time were calculated. Values are the means of triplicate loadings 
plus standard deviation. The effect of different doses of TNF (c) or a combination with interleukin 1 (IL-1) (TNF and IL-1 10 ng/mL) (d) on VEGF-C 
expression at 24 hours was examined by RT-PCR. Experiments were repeated twice with similar results.Available online http://arthritis-research.com/content/9/6/R118
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part of EMD Biosciences, Inc., San Diego, CA, USA) and
found that it inhibited TNF-induced VEGF-C expression in a
dose-dependent manner (Figure 3c). These data support TNF
induction of VEGF-C expression by activation of NF-κB.
CD11b+/Gr-1-/lo cells isolated from joints of tumor 
necrosis factor-transgenic mice express high levels of 
VEGF-C
To examine whether OCPs at the site of inflammation express
VEGF-C, we isolated cells from joints of TNF-Tg mice and WT
littermates using a sequence enzyme digestion method
[26,27]. We obtained, on average, a total of 1.5 × 106 cells
from the four paws of a TNF-Tg mouse. FACS analysis
revealed that approximately 60% of joint cells from TNF-Tg
mice are CD11b+ and almost all of them are Gr-1- (Figure 4a).
Thus, in subsequent experiments, we used only CD11b as a
single marker for OCPs. To determine whether CD11b+ cells
express VEGF-C, we performed double immunofluorescence
staining using anti-CD11b and VEGF-C antibodies in a cyt-
ospin preparation of these cells. There were much more
CD11b and VEGF-C double-stained cells in the joints of TNF-
Tg mice than in WT mice (Figure 4b). We also found that most
of the VEGF-C+ cells are CD11b+, whereas no CD11b- cells
are VEGF-C-, suggesting that VEGF-C is produced in arthritic
joints by OCPs. To examine whether these joint CD11b+ cells
specifically produce more VEGF-C than other VEGFs, we cul-
tured them with M-CSF for 3 days, harvested adherent cells,
and performed real-time reverse transcription-PCR to assess
the expression level of VEGF-A, VEGF-C, and VEGF-D. The
rationale for using these M-CSF-dependent adherent cells is
that they are composed mainly of OCPs and monocytes, as
we described previously [25]. We found that M-CSF-depend-
ent cells that were derived from joints of TNF-Tg mice
expressed much higher levels of VEGF-C  compared with
those of WT mice (Figure 4c) whereas VEGF-A and VEGF-D
levels were similar, suggesting that OCPs/monocytes are the
major source of VEGF-C in arthritic joints of TNF-Tg mice. To
confirm that there is elevated TNF or IL-1 expression in the
joints of TNF-Tg mice, we measured the expression levels of
TNF and IL-1 mRNA and demonstrated that they were remark-
ably increased compared with levels in WT joints (Figure 4d),
which supports the hypothesis that local increased cytokines
stimulate VEGF-C production.
Increased lymphangiogenesis in joints of tumor necrosis 
factor-transgenic mice
Since VEGF-C is a specific lymphatic growth factor [40] and
VEGF-C expression is increased in OCPs, we sought to
determine whether there was increased lymphangiogenesis in
joint sections from TNF-Tg mice compared with WT mice
using immunohistochemistry and an antibody to the lymphatic
endothelial cell marker, LYVE-1. We also assessed, as a pos-
itive control, blood vessels lined by endothelial cells using a
CD31 antibody because these are known to be increased in
TNF-Tg versus WT joints [41]. These results clearly demon-
strated large LYVE-1+  lymphatic vessels compared with
smaller CD31+ vessels in the pannus of TNF-Tg mice (Figure
5a). Histomorphometric quantitation of the area and number of
these lymphatic vessels confirmed a significant increase in
TNF-Tg versus WT joints (Figure 5b). To assess the functional
significance of this increased lymphangiogenesis, we used a
new in vivo MRI technology that we have developed [31] to
see whether the draining popliteal lymph nodes from the knee
and ankle joints of TNF-Tg mice with synovitis are increased
versus WT littermates. Figure 6a demonstrates the remarkable
differences in 2D MRI and 3D reconstructed images of the
synovium and popliteal lymph nodes of TNF-Tg versus WT
mice. Volumetric analyses confirmed that TNF-Tg mice have
significantly larger synovial and popliteal lymph node volumes
compared with WT mice (Figure 6b) and these were con-
firmed with histology (Figure 6c).
To demonstrate that increased lymphangiogenesis is not lim-
ited to the arthritis in TNF-Tg mice and to determine the asso-
ciation between joint inflammation and lymphatic vessel
formation during the course of arthritis induction, we used
mice with K/B × N SIA. This SIA model has clearly distinguish-
able phases of disease progression and uniform severity of
joint lesions among animals compared with TNF-Tg mice. The
SIA mice were sacrificed at 0, 14, and 35 days after K/B × N
serum injection, and joint samples were subjected to histology
and LYVE-1 immunostaining. At day 14 after serum injection,
mice developed severe joint inflammation with pannus forma-
tion and inflammatory cell infiltration, which is accompanied
with increased lymphatic vessel area and number (Figure 7).
By day 35, the inflammation declined, but the lymphatic vessel
formation had increased further (Figure 7) to a degree similar
to that seen in TNF-Tg mice (Figure 5). These data suggest
that increased lymphangiogenesis is a common phenotype of
inflammatory-erosive arthritis.
Discussion
Patients with RA often accompany with enlarged draining
lymph nodes [42] and increased lymph flow rates [43] in
affected limbs, which are correlated with inflamed synovial vol-
ume. However, a cellular and molecular mechanism to explain
these changes has yet to be postulated. In the present study,
we demonstrated that CD11b+/Gr-1-/lo OCPs from joints of
TNF-Tg mice produce high levels of the lymphatic growth fac-
tor, VEGF-C, and that joints from mice in two models of RA
have increased numbers of lymphatic vessels and enlarge-
ment of draining popliteal lymph nodes. Thus, lymphangiogen-
esis is also significantly increased in joints of mice with
inflammatory arthritis. To date, most studies of inflammation-
induced lymphangiogenesis have been performed in animal
models in which the examined tissues have included cornea,
lung, and skin [15,17,44], because frozen sections from these
tissues can be prepared readily for immunostaining to identify
lymphatic vessels and because dye injection can be used to
examine the lymphatic drainage. However, it is difficult to applyArthritis Research & Therapy    Vol 9 No 6    Zhang et al.
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Figure 3
Tumor necrosis factor (TNF) promotes the binding of nuclear proteins to the nuclear factor-kappa B (NF-κB) binding sequences of the vascular  endothelial growth factor-C (VEGF-C) promoter Tumor necrosis factor (TNF) promotes the binding of nuclear proteins to the nuclear factor-kappa B (NF-κB) binding sequences of the vascular 
endothelial growth factor-C (VEGF-C) promoter. Raw264.7 osteoclast/macrophage precursors were cultured in 0.5% bovine serum albumin over-
night. Cells were treated with TNF for 30 to 60 minutes. Nuclear extracts were isolated and subjected to Western blot analysis using anti-NF-κB p65 
and p50 antibodies (a) or to electrophoretic mobility shift assay using a 32P-labeled probe consisting of the putative NF-κB binding sequence of the 
mouse VEGF-C promoter (b). The specificity of binding was confirmed by using 50-fold more unlabeled wild-type (WT) or mutated probe in which 
the putative NF-κB binding sequence was mutated and could not be bound by NF-κB in a competition reaction. An SP-1 probe was used as a load-
ing control. WT osteoclast precursors were treated with TNF ± an NF-κB inhibitor for 24 hours, and expression of VEGF-C was determined by real-
time reverse transcription-polymerase chain reaction. Values are the means of three mice plus standard deviation. (c) The fold decrease in expres-
sion in the NF-κB inhibitor-treated over vehicle-treated cells was calculated. Experiments were repeated two times with similar results.Available online http://arthritis-research.com/content/9/6/R118
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Figure 4
Cells from joints of tumor necrosis factor-transgenic (TNF-Tg) mice express high levels of vascular endothelial growth factor-C (VEGF-C) Cells from joints of tumor necrosis factor-transgenic (TNF-Tg) mice express high levels of vascular endothelial growth factor-C (VEGF-C). Ankle and 
wrist joints of TNF-Tg mice and wild-type (WT) littermates were subjected to collagenase digestion to isolate cells, which then were stained with flu-
orescein isothiocyanate (FITC)-anti-CD11b and phycoerythrin-anti-Gr-1 and subjected to fluorescence-activated cell sorting analysis. (a) The per-
centage of CD11b+/Gr-1-/lo cells is shown in a representative histogram from one pair of TNF-Tg and WT mice. Cells (3 × 105) were cytospun onto 
glass slides and double-stained with FITC-anti-CD11b and rabbit anti-VEGF-C followed by anti-rabbit Alexa 546. TO-PRO-3 iodide was used as a 
DNA dye for nuclear staining. (b) Co-localization of CD11b and VEGF-C proteins was observed, and pictures were taken under a confocal micro-
scope at a power of × 20. Cells were cultured with M-CSF for 3 days, and adherent cells were harvested. (c) Expressions of VEGF-A, -C, and -D 
mRNA were measured by real-time reverse transcription-polymerase chain reaction (RT-PCR). The fold increases in expression in TNF-Tg over WT 
cells were calculated. Values are the means of triplicate loadings plus standard deviation (SD). (d) The expression levels of TNF and IL-1 mRNA in 
joint extracts from TNF-Tg mice and WT littermates were determined by real-time RT-PCR. Values are the means of three mice plus SD. Experiments 
were repeated using four additional pairs of TNF-Tg and WT mice with similar results.Arthritis Research & Therapy    Vol 9 No 6    Zhang et al.
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these methods to joints. Here, we used a combination of
microarrays, FACS, immunohistochemistry, and a novel in vivo
contrast-enhanced-MRI technique to demonstrate that the
lymphatic vasculature in inflamed joints and draining lymph
nodes are significantly increased in mice with TNF and SIA.
Our findings are consistent with those in clinical studies dem-
onstrating increased VEGF-C expression in RA joints [45,46]
and increased size of lymph nodes [43]. Furthermore, based
on increased volume of collected lymph [42] and our
demonstration of increased VEGF-C production by joint
OCPs, we propose that the development of large lymphatic
vessels in the pannus results from proliferation of lymphatic
endothelial cells and their distention by increased amounts of
lymph.
While the origin of lymphatic endothelia cells remains an area
of active research, several studies on inflamed corneas, skin,
and lung have reported the presence of CD11b+ myeloid cells
expressing VEGF-C in these tissues [15,47]. These studies
speculated that inflammatory cytokines stimulate VEGF-C pro-
duction by these CD11b+ cells based on previous work in
human lung fibroblasts and human umbilical vein endothelial
cells [18,19]. Here, we demonstrated that TNF and IL-1 upreg-
ulate VEGF-C expression in CD11b+ OCPs. To validate our
microarray findings and provide insight into the mechanism of
TNF-induced VEGF-C expression in OCPs, we provide prelim-
inary evidence indicating that this response is mediated by NF-
κB-dependent transcription. Since other signal transduction
pathways could also be involved and TNF could be acting indi-
Figure 5
Enlargement of lymphatic vessels in the joints of tumor necrosis factor-transgenic (TNF-Tg) mice Enlargement of lymphatic vessels in the joints of tumor necrosis factor-transgenic (TNF-Tg) mice. Joint sections from TNF-Tg mice or wild-type (WT) 
littermates were immunostained with anti-LYVE-1 or CD31 antibody. (a) Micrographs (× 20) show increased numbers and diameters of LYVE-1+ 
lymphatic vessels in the synovium of TNF-Tg mice. (b) The area and number of lymphatic vessels within the synovium were counted. Values are the 
means plus standard deviation of five TNF-Tg mice and six WT mice. *p < 0.05 versus WT samples. LYVE-1, lymphatic endothelial hyaluronan 
receptor 1.Available online http://arthritis-research.com/content/9/6/R118
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rectly through prostaglandins [48], which also mediate VEGF-
C transcription in cancer cells [49], future studies are needed
to elucidate the mechanisms of inflammation-induced VEGF-C
expression in OCPs.
Considering the cellular heterogeneity of joint pannus, it is
important to determine the primary source of VEGF-C in
arthritic joints. While our studies focused on OCPs, others
have shown that TNF and/or IL-1 stimulates VEGF-C expres-
sion by human lung fibroblasts, blood vascular endothelial
cells, and synovial cells [19,46]. We found that TNF also stim-
ulates VEGF-C expression in NIH3T3 and C2C12 fibroblast
cell lines (data not shown), suggesting that fibroblast-like cells
in synovium could perhaps be another source of VEGF-C in
arthritic pannus. However, these results were obtained from in
vitro treatment of cells with cytokines and may not precisely
reflect the in vivo situation, particularly in the joint local micro-
environment. Our immunocytochemistry studies using cells
freshly isolated from joints demonstrated that most of the
VEGF-C-expressing cells are CD11b+  (Figure 4b). One
potential concern with this approach is that primary joint cells
are composed of a mixture of cell types. To address this limi-
tation, we cultured these cells with M-CSF and used only
adherent cells for further study. Under these culture condi-
tions, more than 90% of adherent cells are CD11b+/Gr-1-/lo
OCPs (Q. Zhang, Y. Lu, S. Proulx, R. Guo, Z. Yao, E.M.
Schwarz, B.F. Boyce, L. Xing, unpublished data). We found
that these M-CSF-dependent joint cells express much higher
levels of VEGF-C than cells treated in vitro (20- to 30-fold
increase in joint cells in Figure 3c versus 3- to 5-fold increase
in TNF-treated cells in Figure 2a). Thus, although other cell
types may also be VEGF-C-producing cells, CD11b+/Gr-1-/lo
OCPs likely are one of the major sources of VEGF-C in joint
pannus.
Our findings demonstrated that increased lymphangiogenesis
is associated with the progression of joint inflammation, which
occurs not only in dysregulated TNF-induced arthritis (Figure
5) but also in mice with SIA (Figure 7). A recent study reported
that, in joint sections of collagen-induced arthritis, the number
of LYVE-1+ lymphatic vessels is increased [50]. Thus, elevated
lymphangiogenesis likely is a common feature of inflammatory
arthritis. Inflammation-induced lymphangiogenesis in joints
appears to be a slow process, taking 2 to 3 weeks (Figure 7).
Our explanation is that OCPs or other VEGF-C-producing
cells may need to migrate to the inflamed joints first and then
respond to elevated cytokine levels to produce VEGF-C,
which then stimulates formation of lymphatic endothelial cells.
Interestingly, increased lymphatic vasculature persists even
after serum-induced inflammation has resolved (Figure 7). This
is consistent with our observation of no change in lymphatic
vessel area or number in TNF-Tg mice with a significant
reduction in their joint inflammation after anti-TNF therapy
treatment (see Additional File 1). Persistent lymphangiogen-
esis was also reported in a mouse model of chronic respiratory
tract infection in which inflammation has been cured by antibi-
otics [17]. Currently, there is no explanation why these lym-
phatic vessels do not disappear along with the reduction in
inflammation. One speculation is that lymphatic enlargement
makes affected tissues more susceptible to later inflammation
by facilitating the accumulation of immune cells at the site of
injury or infection [51]. However, it is also possible that an
increased lymphatic network will prime tissues to respond to
acute inflammation.
Figure 6
Increased volume of popliteal lymph nodes in tumor necrosis factor- transgenic (TNF-Tg) mice Increased volume of popliteal lymph nodes in tumor necrosis factor-
transgenic (TNF-Tg) mice. (a) A representative post-contrast magnetic 
resonance imaging slice from a TNF-Tg and wild-type (WT) mouse (5 
months old). (b) Using a semi-automated segmentation procedure in 
Amira software, the synovial (yellow) and lymph node (red) volumes 
were quantified and visualized in TNF-Tg and WT mice. *p < 0.05 ver-
sus WT samples (n = 5). (c) Representative hematoxylin-and-eosin 
sections (× 4) demonstrate differences in lymph node size between 
TNF-Tg and WT animals.Arthritis Research & Therapy    Vol 9 No 6    Zhang et al.
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A central question that arises from our study and other recent
studies regarding inflammation-induced lymphangiogenesis is
whether lymphangiogenesis in arthritis is beneficial or harmful
to affected joints. Early clinical studies proposed that inflam-
mation-driven lymphangiogenesis induces the expansion of
the lymphatic network in an exacerbated manner such that the
lymphatic vessels may be dysfunctional, as reported in
psoriasis and Crohn disease [52-54]. Recently, VEGF-C or
VEGFR-3 antagonists have been used to directly stimulate or
block VEGF-C/VEGFR-3-mediated lymphangiogenesis in sev-
eral models of inflammation. In general, the effects of
manipulating lymphangiogenesis in inflammatory conditions
are not clear and appear to be largely dependent on the type
of model used. For example, in the corneal transplantation
model, lymphangiogenesis and angiogenesis are increased by
grafting, and blockade of either form of new vessel formation
has a similar beneficial effect and prevents graft rejection [55].
In contrast, UVB-induced skin inflammation is exacerbated by
VEGF-C antagonism [56], suggesting that stimulation of the
lymphatic system might reduce disease severity. Thus, the
functional importance of lymphangiogenesis in the pathogen-
esis of RA remains to be determined.
Conclusion
Our findings demonstrate that lymphangiogenesis is signifi-
cantly increased in joints of mice with inflammatory arthritis.
TNF and OCPs appear to play a critical role in initiating this
process through stimulation of VEGF-C production.
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